The US FDA denied EUA for Zyesami to treat critical Covid-19 patients with respiratory failure. Credit: CDC / Unsplash.

The US Food and Drug Administration (FDA) has declined to grant an emergency use authorization (EUA) for NRx Pharmaceuticals’ therapy, Zyesami (aviptadil), to treat critical Covid-19 patients who have respiratory failure.

In a letter to the company, the agency noted that its decision comes due to inadequate evidence on the known and possible benefits of the treatment and its risks in critical Covid-19 patients with respiratory failure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FDA has so far assessed safety in 131 randomised subjects who received Zyesami.

NRx will work with the FDA to arrange an analysis of the 150 or more subjects who were given Zyesami treatment in the ACTIV-3b Critical Care clinical trial sponsored by the US National Institutes of Health (NIH).

The Data Safety and Monitoring Board of the Phase III trial assessed the data and reported no new safety concerns linked to the treatment.

Trials of Zyesami, funded by the NIH and US Biomedical Advanced Research and Development Authority, are underway and are progressing towards enrolment in Europe and Brazil.

NRx Pharmaceuticals board chairman and CEO Jonathan Javitt said: “We believe that Zyesami has demonstrated a high degree of safety and a two-fold increase in the odds of surviving the ICU.

“We will work actively with the FDA to deliver the data it has requested so that we may offer those patients another chance at life and have asked the FDA for a Type A meeting that will include the experience of physicians who have witnessed the effects of our medicine firsthand and the experience of patients who are alive today because they were given one last chance at life.”

The company sought a Type A meeting with FDA authorities last week to discuss the experimental treatment’s development.

Currently, Zyesami is accessible for people in the country at the request of the doctor.